Ilise Lombardo, clinical research head of Axovant Sciences Ltd., said the firm’s ongoing efforts will “certainly be informed” by the late-stage clinical work with approved pimavanserin (Nuplazid, Acadia Pharmaceuticals Inc.) as tests proceed with similarly 5HT2A-targeting nelotanserin.